Background Bell's palsy is a rare adverse event reported in clinical trials of COVID-19
vaccines. However, to our knowledge no population-based study has assessed the …

Background An excess risk of Bell's palsy has been suggested after mRNA vaccines. We
examined the association between the BNT162b2 mRNA COVID-19 vaccine and Bell's …

Abstract Coronavirus disease 2019 (COVID-19) has become the fastest-spreading
pandemic of the 21st century. Various vaccines have been made available via emergency …

4 Erdur H, Ernst S, Ahmadi M, et al. Evidence for seasonal variation of Bell's palsy in
Germany. Neuroepidemiology 2018; 51: 128–30. seen in the Oxford-AstraZeneca and …

In light of the ongoing pandemic, development of vaccines to protect against SARS-CoV-2
infection and COVID-19 disease is an important public health priority. As of February 2021 …

In the past 100 days, more than 3 billion doses of SARS-CoV-2 vaccines have been
administered globally. 1 With 20 vaccines currently authorised in at least one country and …

Objectives: Facial nerve palsy (or Bell's palsy) has occasionally been reported following the
administration of coronavirus disease 2019 (COVID-19) mRNA vaccines (BNT162b2 and …

Objective To report a patient with history of recurrent Bell's Palsy who developed Bell's Palsy
36​ h after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine …

Importance Bell palsy (BP) has been reported as an adverse event following the SARS-CoV-
2 vaccination, but neither a causative relationship nor a higher prevalence than in the …

Currently two Coronavirus Disease 2019 (COVID-19) vaccines have been granted
emergency use and marketing authorization by the US Food and Drug Administration (FDA) …